Two Fraction Prostate SBRT With DIL SIB

Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer. The primary purpose of this study is to determine the feasibility and safety of two fraction SBRT in patients with localized prostate cancer.

Trial Details

NCT ID

NCT05864196

Phase

PHASE1

Sponsor

NYU Langone Health

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Two-Fraction Stereotactic Body Radiation Therapy (SBRT)

Locations (sample)

Mineola, New York, United States|40.74927,-73.64068
New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

Patient age greater than or equal 18
Localized adenocarcinoma of the prostate
Biopsy-proven diagnosis of prostate adenocarcinoma
Low to intermediate risk National Comprehensive Cancer Network (NCCN) disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →